Summary

The global Blood-Brain Barrier Transport Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Blood-Brain Barrier Transport Drugs Industry Forecast” looks at past sales and reviews total world Blood-Brain Barrier Transport Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Blood-Brain Barrier Transport Drugs sales for 2025 through 2031. With Blood-Brain Barrier Transport Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Blood-Brain Barrier Transport Drugs industry.
This Insight Report provides a comprehensive analysis of the global Blood-Brain Barrier Transport Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Blood-Brain Barrier Transport Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Blood-Brain Barrier Transport Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Blood-Brain Barrier Transport Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Blood-Brain Barrier Transport Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Blood-Brain Barrier Transport Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Carrier-mediated Transport
Receptor-mediated Transport
Absorptive-mediated Transport
Active Efflux Transport
Others
Segmentation by Application:
Alzheimer's Disease
Epilepsy
Parkinson's Disease
Multiple Sclerosis
Hunter's Syndrome
Brain Cancer
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Cyclenium
BioAdvance
EIP Pharma
Bioasis
Immune Pharmaceuticals
AZ Therapies
Palobiofarma
Bach Pharma
BrainsGate
CarThera
Dainippon Sumitomo Pharma
Fluorinov Pharma
Fondazione Telethon
Minoryx
NewGen Therapeutics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Blood-Brain Barrier Transport Drugs market?
What factors are driving Blood-Brain Barrier Transport Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Blood-Brain Barrier Transport Drugs market opportunities vary by end market size?
How does Blood-Brain Barrier Transport Drugs break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Blood-Brain Barrier Transport Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Blood-Brain Barrier Transport Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Blood-Brain Barrier Transport Drugs by Country/Region, 2020, 2024 & 2031
2.2 Blood-Brain Barrier Transport Drugs Segment by Type
2.2.1 Carrier-mediated Transport
2.2.2 Receptor-mediated Transport
2.2.3 Absorptive-mediated Transport
2.2.4 Active Efflux Transport
2.2.5 Others
2.3 Blood-Brain Barrier Transport Drugs Sales by Type
2.3.1 Global Blood-Brain Barrier Transport Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Blood-Brain Barrier Transport Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Blood-Brain Barrier Transport Drugs Sale Price by Type (2020-2025)
2.4 Blood-Brain Barrier Transport Drugs Segment by Application
2.4.1 Alzheimer's Disease
2.4.2 Epilepsy
2.4.3 Parkinson's Disease
2.4.4 Multiple Sclerosis
2.4.5 Hunter's Syndrome
2.4.6 Brain Cancer
2.4.7 Others
2.5 Blood-Brain Barrier Transport Drugs Sales by Application
2.5.1 Global Blood-Brain Barrier Transport Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Blood-Brain Barrier Transport Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Blood-Brain Barrier Transport Drugs Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Blood-Brain Barrier Transport Drugs Breakdown Data by Company
3.1.1 Global Blood-Brain Barrier Transport Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Blood-Brain Barrier Transport Drugs Sales Market Share by Company (2020-2025)
3.2 Global Blood-Brain Barrier Transport Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Blood-Brain Barrier Transport Drugs Revenue by Company (2020-2025)
3.2.2 Global Blood-Brain Barrier Transport Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Blood-Brain Barrier Transport Drugs Sale Price by Company
3.4 Key Manufacturers Blood-Brain Barrier Transport Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Blood-Brain Barrier Transport Drugs Product Location Distribution
3.4.2 Players Blood-Brain Barrier Transport Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Blood-Brain Barrier Transport Drugs by Geographic Region
4.1 World Historic Blood-Brain Barrier Transport Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Blood-Brain Barrier Transport Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Blood-Brain Barrier Transport Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Blood-Brain Barrier Transport Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Blood-Brain Barrier Transport Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Blood-Brain Barrier Transport Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Blood-Brain Barrier Transport Drugs Sales Growth
4.4 APAC Blood-Brain Barrier Transport Drugs Sales Growth
4.5 Europe Blood-Brain Barrier Transport Drugs Sales Growth
4.6 Middle East & Africa Blood-Brain Barrier Transport Drugs Sales Growth
5 Americas
5.1 Americas Blood-Brain Barrier Transport Drugs Sales by Country
5.1.1 Americas Blood-Brain Barrier Transport Drugs Sales by Country (2020-2025)
5.1.2 Americas Blood-Brain Barrier Transport Drugs Revenue by Country (2020-2025)
5.2 Americas Blood-Brain Barrier Transport Drugs Sales by Type (2020-2025)
5.3 Americas Blood-Brain Barrier Transport Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Blood-Brain Barrier Transport Drugs Sales by Region
6.1.1 APAC Blood-Brain Barrier Transport Drugs Sales by Region (2020-2025)
6.1.2 APAC Blood-Brain Barrier Transport Drugs Revenue by Region (2020-2025)
6.2 APAC Blood-Brain Barrier Transport Drugs Sales by Type (2020-2025)
6.3 APAC Blood-Brain Barrier Transport Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Blood-Brain Barrier Transport Drugs by Country
7.1.1 Europe Blood-Brain Barrier Transport Drugs Sales by Country (2020-2025)
7.1.2 Europe Blood-Brain Barrier Transport Drugs Revenue by Country (2020-2025)
7.2 Europe Blood-Brain Barrier Transport Drugs Sales by Type (2020-2025)
7.3 Europe Blood-Brain Barrier Transport Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Blood-Brain Barrier Transport Drugs by Country
8.1.1 Middle East & Africa Blood-Brain Barrier Transport Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Blood-Brain Barrier Transport Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Blood-Brain Barrier Transport Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Blood-Brain Barrier Transport Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Blood-Brain Barrier Transport Drugs
10.3 Manufacturing Process Analysis of Blood-Brain Barrier Transport Drugs
10.4 Industry Chain Structure of Blood-Brain Barrier Transport Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Blood-Brain Barrier Transport Drugs Distributors
11.3 Blood-Brain Barrier Transport Drugs Customer
12 World Forecast Review for Blood-Brain Barrier Transport Drugs by Geographic Region
12.1 Global Blood-Brain Barrier Transport Drugs Market Size Forecast by Region
12.1.1 Global Blood-Brain Barrier Transport Drugs Forecast by Region (2026-2031)
12.1.2 Global Blood-Brain Barrier Transport Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Blood-Brain Barrier Transport Drugs Forecast by Type (2026-2031)
12.7 Global Blood-Brain Barrier Transport Drugs Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Cyclenium
13.1.1 Cyclenium Company Information
13.1.2 Cyclenium Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.1.3 Cyclenium Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Cyclenium Main Business Overview
13.1.5 Cyclenium Latest Developments
13.2 BioAdvance
13.2.1 BioAdvance Company Information
13.2.2 BioAdvance Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.2.3 BioAdvance Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 BioAdvance Main Business Overview
13.2.5 BioAdvance Latest Developments
13.3 EIP Pharma
13.3.1 EIP Pharma Company Information
13.3.2 EIP Pharma Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.3.3 EIP Pharma Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 EIP Pharma Main Business Overview
13.3.5 EIP Pharma Latest Developments
13.4 Bioasis
13.4.1 Bioasis Company Information
13.4.2 Bioasis Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.4.3 Bioasis Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Bioasis Main Business Overview
13.4.5 Bioasis Latest Developments
13.5 Immune Pharmaceuticals
13.5.1 Immune Pharmaceuticals Company Information
13.5.2 Immune Pharmaceuticals Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.5.3 Immune Pharmaceuticals Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Immune Pharmaceuticals Main Business Overview
13.5.5 Immune Pharmaceuticals Latest Developments
13.6 AZ Therapies
13.6.1 AZ Therapies Company Information
13.6.2 AZ Therapies Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.6.3 AZ Therapies Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 AZ Therapies Main Business Overview
13.6.5 AZ Therapies Latest Developments
13.7 Palobiofarma
13.7.1 Palobiofarma Company Information
13.7.2 Palobiofarma Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.7.3 Palobiofarma Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Palobiofarma Main Business Overview
13.7.5 Palobiofarma Latest Developments
13.8 Bach Pharma
13.8.1 Bach Pharma Company Information
13.8.2 Bach Pharma Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.8.3 Bach Pharma Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Bach Pharma Main Business Overview
13.8.5 Bach Pharma Latest Developments
13.9 BrainsGate
13.9.1 BrainsGate Company Information
13.9.2 BrainsGate Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.9.3 BrainsGate Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 BrainsGate Main Business Overview
13.9.5 BrainsGate Latest Developments
13.10 CarThera
13.10.1 CarThera Company Information
13.10.2 CarThera Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.10.3 CarThera Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 CarThera Main Business Overview
13.10.5 CarThera Latest Developments
13.11 Dainippon Sumitomo Pharma
13.11.1 Dainippon Sumitomo Pharma Company Information
13.11.2 Dainippon Sumitomo Pharma Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.11.3 Dainippon Sumitomo Pharma Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Dainippon Sumitomo Pharma Main Business Overview
13.11.5 Dainippon Sumitomo Pharma Latest Developments
13.12 Fluorinov Pharma
13.12.1 Fluorinov Pharma Company Information
13.12.2 Fluorinov Pharma Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.12.3 Fluorinov Pharma Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Fluorinov Pharma Main Business Overview
13.12.5 Fluorinov Pharma Latest Developments
13.13 Fondazione Telethon
13.13.1 Fondazione Telethon Company Information
13.13.2 Fondazione Telethon Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.13.3 Fondazione Telethon Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Fondazione Telethon Main Business Overview
13.13.5 Fondazione Telethon Latest Developments
13.14 Minoryx
13.14.1 Minoryx Company Information
13.14.2 Minoryx Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.14.3 Minoryx Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Minoryx Main Business Overview
13.14.5 Minoryx Latest Developments
13.15 NewGen Therapeutics
13.15.1 NewGen Therapeutics Company Information
13.15.2 NewGen Therapeutics Blood-Brain Barrier Transport Drugs Product Portfolios and Specifications
13.15.3 NewGen Therapeutics Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 NewGen Therapeutics Main Business Overview
13.15.5 NewGen Therapeutics Latest Developments
14 Research Findings and Conclusion